SOURCE: Active Biotech

March 22, 2007 03:30 ET

Invitation to Annual General Meeting of Shareholders

LUND, SWEDEN -- (MARKET WIRE) -- March 22, 2007 -- The Board of Directors of Active Biotech AB (publ) has today issued a notification of the Annual General Meeting, which is to take place at 5 pm on 19 April 2007 at the company's premises at Scheelevägen 22 in Lund.

The notification is published in today's editions of Svenska Dagbladet and Post- och Inrikes Tidningar.

Lund 22 March, 2007



Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB ( 556223-9227)
P.O Box 724, SE-220 07 Lund, Sweden
Tel +46 46-19 20 00
Fax +46 46-19 20 50
Invitation to Annual General Meeting of Shareholders:

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information